$IBRX Cashflow Statement | Understand Stock

$IBRX

$8.63 +$0.82 (10.5%) Close

$IBRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense related to revenue interest liability
Stock-based compensation expense
Change in fair value of derivative liabilities
Amortization of related-party notes discounts
Depreciation and amortization
Change in fair value of warrant liabilities
Non-cash interest items, net
Non-cash lease expense related to operating lease right-of-use assets
Nonrelated Party
Related Party
Total non-cash lease expense related to operating lease right-of-use assets
Non-cash interest items, net (including amounts with related parties)
Unrealized losses on equity securities
Unrealized loss on non-marketable equity investment
Change in fair value of related-party convertible note
Related Party
Total change in fair value of related-party convertible note
Transaction costs allocated to warrant liabilities
Impairment of intangible assets
Loss on equity method investment
Deferred tax
Loss due to write-off of fixed assets
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Nonrelated Party
Related Party
Total prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other liabilities
Due to and due from related parties, net
Operating lease liabilities
Nonrelated Party
Related Party
Total operating lease liabilities
Net cash used in operating activities

Investing activities:
Purchases of marketable debt securities, available-for-sale
Proceeds from maturities of marketable debt securities, available-for-sale
Proceeds from sales of marketable debt securities, available-for-sale
Payment to Precision Biologics to facilitate deconsolidation
Purchase of non-marketable equity investment
Purchases of property, plant and equipment
Software development costs
Acquisition of a business, net of transaction costs
Cash paid for other investments
Purchase of intangible assets
Proceeds from sales of property, plant and equipment
Investment in joint venture – an equity method investment
Net cash used in investing activities

Financing activities:
Proceeds from equity offerings, net of discounts and issuance costs
Private Placement and At The Market Offerings
Stock Purchase and Option Agreement
Total proceeds from equity offerings, net of discounts and issuance costs

Proceeds from short-term borrowings
Principal payments on premium financing
Net share settlement for RSUs vesting
Proceeds from exercise of Oberland stock option, net of commissions
Options, Excluding Stock Purchase and Option Agreement
Stock Purchase and Option Agreement
Total proceeds from exercise of Oberland stock option, net of commissions
Principal payments of finance leases
Sale of assets to an entity under common control
Proceeds from Second Payment, net of issuance costs
Proceeds from exercises of warrants
Repurchase of common stock
Proceeds from issuance of related-party promissory notes, net of issuance costs paid
Payment for contingent consideration
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents, and restricted cash
Net change in cash and cash equivalents, and restricted cash
Cash and cash equivalents, and restricted cash, beginning of year
Cash and cash equivalents, and restricted cash, end of year
Supplemental disclosure of cash flow information:
Interest
Income taxes
Non-cash investing and financing activities:
Initial measurement of warrants issued in connection with equity offerings accounted for as liabilities
Issuance of common stock upon vesting of RSUs
Cashless exercise of stock options
Accrued investment in joint venture
Issuance of equity for warrant exercise via reduction of related-party promissory notes
Right-of-use assets obtained in exchange for operating lease liabilities
Property and equipment purchases included in accounts payable, accrued expenses and other liabilities, and due to related parties
Right-of-use assets obtained in exchange for finance lease liabilities
Unrealized losses on marketable debt securities, net
Unpaid offering costs included in accounts payable, and accrued expenses and other liabilities
Conversion of related-party convertible notes and accrued interest, net of unamortized discount, into equity
Gain on extinguishment of debt with related parties under common control
Increase in fair value of embedded conversion feature from debt modification
Change in ownership interest in a joint venture due to legal settlement
Common stock issuance discount related to revenue interest liability
Right-of-use assets disposed in exchange for operating lease liabilities

Reconciliation of cash, cash equivalents, and restricted cash, end of year:
Cash and cash equivalents
Restricted cash

Comments